Clinical trial
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic…
NCT00005618 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005618 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia |
| Official title | Phase II Study of Arsenic Trioxide, NSC 706363, in Relapsed of Refractory Chronic Myelogenous Leukemia |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Start date | Feb 1, 2000 |
| Completion | Mar 1, 2004 |
| First posted | Apr 2, 2004 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: